



Universiteit  
Leiden  
The Netherlands

## Pharmacotherapy and ventilatory control in health and disease

Simons, P.

### Citation

Simons, P. (2024, June 5). *Pharmacotherapy and ventilatory control in health and disease*. Retrieved from <https://hdl.handle.net/1887/3762198>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3762198>

**Note:** To cite this publication please use the final published version (if applicable).

---

**Pharmacotherapy**  
**and**  
**Ventilatory Control**  
in Health and Disease

Pieter Simons

---

The investigations described in chapters 2-5 of this thesis were performed in the Anesthesia & Pain Research Unit, Leiden University Medical Center, under the supervision of prof. dr. A. Dahan and dr. R. van der Schrier.

Copyright © 2024 *Pieter Simons*.

ISBN 978-94-6506-095-8

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without prior permission of the author.

Typeset by L<sup>A</sup>T<sub>E</sub>X

Cover design by Anneriek Simons

Printed by Ridderprint, the Netherlands

The printing of this thesis was financially supported by: ChipSoft and Trevena.

---

# Pharmacotherapy and Ventilatory Control

## in Health and Disease

Proefschrift

ter verkrijging van  
de graad van Doctor aan de Universiteit Leiden,  
op gezag van rector magnificus prof. dr. ir. H. Bijl,  
volgens besluit van het college voor promoties  
te verdedigen op woensdag 5 juni 2024  
klokke 11:15 uur

door

Pieter Simons  
geboren te Enschede  
in 1991

---

## Promotiecomissie

Promotor: Prof. dr. A. Dahan

Copromotores: Dr. M. Niesters  
Dr. M. van Velzen

Commissie: Prof. dr. E.Y. Sarton  
Prof. dr. S. B. Karan (Rochester Medical Center)  
Prof. dr. dr. M.W. Hollmann (Amsterdam UMC)  
Prof. dr. H. Pijl  
Prof. dr. J. Swen

---

*The marriage of breath and beat is critical for life.*

Ken D. O'Halloran - 2023



# Contents

1	Introduction	1
2	<i>S</i> -ketamine oral thin film pharmacokinetics	13
3	<i>S</i> -ketamine oral thin film pharmacodynamics	41
4	Oliceridine respiratory effects	65
5	Diabetes, hyperinsulinemia, and the hypoxic ventilatory response	99
6	Summary, conclusions, and perspectives	121
7	Nederlandse samenvatting	131
	Addenda	135



# List of Figures

2.1	<i>S</i> -ketamine PK - Plasma concentrations . . . . .	22
2.2	<i>S</i> -ketamine PK - Final PK model . . . . .	26
2.3	<i>S</i> -ketamine PK - Goodness of Fit (GOF) plots . . . . .	30
2.4	<i>S</i> -ketamine PK - Simulations . . . . .	31
2.5	<i>S</i> -ketamine PK - Simulations HNK . . . . .	35
3.1	<i>S</i> -ketamine PD - Pharmacokinetic data . . . . .	49
3.2	<i>S</i> -ketamine PD - Antinociceptive data . . . . .	49
3.3	<i>S</i> -ketamine PD - Goodness-of-Fit plots . . . . .	52
3.4	<i>S</i> -ketamine PD - Drug high data . . . . .	53
3.5	<i>S</i> -ketamine PD - Visual Predictive Checks . . . . .	54
3.6	<i>S</i> -ketamine PD - Steady-state concentration-effect relationships .	55
4.1	Oliceridine respiratory effects - $\dot{V}_{E55}$ for four treatment arms . .	74
4.2	Oliceridine respiratory effects - Mean pharmacokinetic data . . .	76
4.3	Oliceridine respiratory effects - Goodness-of-Fit PK data . . . . .	77
4.4	Oliceridine respiratory effects - Population PK model outcome .	78
4.5	Oliceridine respiratory effects - Population PD model outcome .	81
4.6	Oliceridine respiratory effects - Goodness-of-Fit PD data . . . . .	82
4.7	Oliceridine respiratory effects - Simulation multiple dosing . . . .	85
4.8	Oliceridine respiratory effects - Queried adverse events . . . . .	87
5.1	CB Hypoxia - Strobe diagram . . . . .	105
5.2	CB Hypoxia - HVR . . . . .	108
5.3	CB Hypoxia - Dejour . . . . .	109
5.4	CB Hypoxia - Hemodynamics . . . . .	111



## List of Tables

2.1	<i>S</i> -ketamine PK - Subject characteristics . . . . .	20
2.2	<i>S</i> -ketamine PK - Pharmacokinetic parameters OTF . . . . .	23
2.3	<i>S</i> -ketamine PK - Adverse effects . . . . .	24
2.4	<i>S</i> -ketamine PK - OTF pharmacokinetics . . . . .	27
3.1	<i>S</i> -ketamine PD - Pharmacodynamic parameter estimates . . . . .	51
4.1	Oliceridine respiratory effects - PK parameter estimates . . . . .	79
4.2	Oliceridine respiratory effects - PD parameter estimates . . . . .	83
4.3	Oliceridine respiratory effects - Adverse effects . . . . .	86
5.1	CB Hypoxia - Subject characteristics . . . . .	106